Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Accelerated Approval
View:
Post by Quentin30 on Aug 01, 2024 5:01pm

Accelerated Approval

Interesting, another Phase II (so smaller than a phase III), and then apply for accelerated approval..

So Noteable, the first time ONCY has specifically mentioned AA...  that's a positive. The downside of course is how long it will take to get the data to run the study... Given that they haven't acknowledged submission of a CTA. I would expect ONCY to be in a position to apply for accelerated approval in mid 2026. If then approved late 2026/early 2027, they would be able to market Pela (with realtime Phase IV trial). Pity they only have cash till early 2025...

look out for dilution.
Comment by Noteable on Aug 01, 2024 5:06pm
You once again have a disconnect between when the accelerated approval would be granted and when the Phase 3 would be run, particualrly since the BRACELET-1  OS data is expected later this half and more likely later this quarter.
Comment by Quentin30 on Aug 01, 2024 6:46pm
Accelerated Approval granted in PLACE of running a Phase III trial... x 2 randomised Phase II trials... so they need to complete the mentioned next phase II... still doesn't really matter... I've had enough of ONCY... sold out my last positions over a month ago.. you're just trumping to an audience of half a dozen really... nobody really gives a stuff about this company... step up ...more  
Comment by Noteable on Aug 01, 2024 6:56pm
Two ONCY Phase 2 metastatic Breast cancers have been completed namely IND-213 and Bracelet-1. ONCY will be reporting on the 2 year overall survival (OS) results this half or more likely this quarter of this year. Accelerated Approval is usually granted on this endpoint, and a confirmatory trial will follow.  OK. I will note that you have no position in ONCY and are here only to agitate.
Comment by Noteable on Aug 01, 2024 7:03pm
Well let me remind you that there are 72 million reasons why "somebody" gives a ' down-under stuff ' about this company.
Comment by 13X2413 on Aug 01, 2024 7:57pm
Like I said earlier. More news from this POS, more sellers tomorrow. This is fading fast, just like my money tied up in this. My hopes for a miracle turnaround are in the dumpster. 
Comment by Azzak34 on Aug 01, 2024 8:19pm
Good. Come back tomorrow and tell me more happy news about your dumpster life. 
Comment by Noteable on Aug 01, 2024 10:00pm
Stocktwits' Scooter0732 who is a big holder of Agenus Inc.  doesn't appear to understand that with an Accelerated Approval comes a revenue stream or an accretive Big Pharma acquisition. Maybe he will someday.
Comment by Azzak34 on Aug 01, 2024 10:07pm
Big Ole bag holder. He is a dope. 
Comment by Noteable on Aug 01, 2024 11:54pm
https://seekingalpha.com/news/4125535-agenus-stock-plunges-on-fda-feedback-on-botbal-therapy https://www.wfxrtv.com/business/press-releases/accesswire/890282/agen-shareholder-alert-bronstein-gewirtz-and-grossman-llc-announces-an-investigation-into-agenus-inc-and-encourages-shareholders-to-contact-the-firm-today/ Regarding the above on AGEN https://www.wrbl.com/business/press-releases/accesswire ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities